ClinicalTrials.Veeva

Menu

Interest of the Donor-specific Antibodies After Liver Transplantation (vaLIDLIver)

U

University Hospital, Lille

Status

Completed

Conditions

Liver Transplant

Study type

Observational

Funder types

Other

Identifiers

NCT03238443
2014_18
2015-A00418-41 (Other Identifier)

Details and patient eligibility

About

The study is a prospective observational mono center study

Primary objective :

Study the anti-HLA antibodies frequency preformed before liver transplantation and the kinetic of appearance of DSA and de novo complement-binding anti-HLA antibodies after liver transplantation.

Secondary objective :

  • Risk factor of de novo DSA appearance (Immunosuppressive therapy, liver aetiology)

  • Impact of DSA on:

    • Graft and patients survivals
    • Onset of allograft rejection (acute, late-onset, chronic)
    • Unexplained liver graft dysfunction
    • Unexplained liver enzymes abnormalities
    • Liver fibrosis development (liver stiffness study using fibroscan©)

Enrollment

120 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Liver transplanted patients older than 18, transplanted in Lille University Hospital.
  • Written consent by the patient or his/her legal representative (especially patient with hepatic encephalopathy).
  • Patients with health insurance

Exclusion criteria

  • Minor patients.
  • Pregnant women or during lactation.
  • Patient under curatorship.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems